N-of-One® dramatically speeds high-accuracy interpretation of the Illumina TrueSight Tumor170 Cancer Panel

Concord, Mass. February 21, 2017 – N-of-One, Inc., founded in 2008 as a leader in interpretation of molecular tests in oncology, announced today the launch of RapidInsights for Illumina’s TruSight Tumor 170 (TST170). RapidInsights is a fully automated interpretation solution that, in a matter of minutes, will read the bioinformatics output of the genomic variants […]